{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:09:47Z","timestamp":1784221787141,"version":"3.55.0"},"reference-count":22,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The Anyplex II HPV HR detection kit (Seegene Inc, Seoul, Korea) is a new, multiplex, real-time polymerase chain reaction assay to detect individual 14 high-risk (HR) human papillomavirus (HPV) types in a single tube.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical performance of the HPV HR kit in predicting high-grade squamous intraepithelial lesions and cervical intraepithelial lesions grade 2 or worse in cervical cancer screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We analyzed 1137 cervical samples in Huro Path medium (CelltraZone, Seoul, Korea) from Korean women. The clinical performance of the HPV HR kit was compared with Hybrid Capture 2 (Qiagen, Valencia, California) using the noninferiority score test in a routine cervical cancer screening setting. The intralaboratory and interlaboratory agreements of HPV HR were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall agreement between the 2 assays was 92.4% (1051 of 1137) with a \u03ba value of 0.787. Clinical sensitivity of HPV HR for high-grade squamous intraepithelial lesions and cervical intraepithelial lesions grade 2 or worse was 94.4% (95% confidence interval [CI], 89.2\u201399.7) and 92.5% (95% CI, 84.3\u2013100.0), respectively. The respective values for Hybrid Capture 2 were 93.1% (95% CI, 87.2\u201398.9) and 87.5% (95% CI, 77.3\u201399.7). Clinical sensitivity and specificity of HPV HR were not inferior to those of Hybrid Capture 2 (P = .005 and P = .04, respectively). The HPV HR showed good intralaboratory and interlaboratory reproducibility at 98.0% (\u03ba = 0.953) and 97.4% (\u03ba = 0.940), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The HPV HR demonstrates comparable performance to the Hybrid Capture 2 test and can be useful for HPV-based cervical cancer screening testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2015-0117-oa","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T12:10:23Z","timestamp":1456747823000},"page":"276-280","source":"Crossref","is-referenced-by-count":27,"title":["Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea"],"prefix":"10.5858","volume":"140","author":[{"given":"Sunkyung","family":"Jung","sequence":"first","affiliation":[{"name":"From the Molecular Diagnostics Testing Center (Drs Jung and K. N. Lee)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byungdoo","family":"Lee","sequence":"additional","affiliation":[{"name":"and the Department of Pathology (Dr B. Lee),"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kap No","family":"Lee","sequence":"additional","affiliation":[{"name":"Seegene Medical Foundation, Seocho-gu, Seoul, Republic of Korea; and the Department of Laboratory Medicine, College of Medicine, Seoul St. Mary's Hospital, Catholic University of Korea (Drs Kim and Oh)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"4","key":"2020081217003385900_i1543-2165-140-3-276-b01","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","article-title":"WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses","volume":"6","author":"Coglino","year":"2005","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020081217003385900_i1543-2165-140-3-276-b02","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"2020081217003385900_i1543-2165-140-3-276-b03","article-title":"FDA approves first human papillomavirus test for primary cervical cancer screening"},{"issue":"3","key":"2020081217003385900_i1543-2165-140-3-276-b04","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"2020081217003385900_i1543-2165-140-3-276-b05","unstructured":"Anyplex II HPV HR detection kit [package insert]. Seoul, Korea: Seegene Inc;2013."},{"key":"2020081217003385900_i1543-2165-140-3-276-b06","first-page":"5","article-title":"TOCE: innovative technology for high multiplex real-time PCR","volume":"1","author":"Lee","year":"2012","journal-title":"Seegene Bull"},{"key":"2020081217003385900_i1543-2165-140-3-276-b07","first-page":"11","article-title":"Cyclic-CMTA: an innovative concept in multiplex quantification","volume":"1","author":"Hwang","year":"2012","journal-title":"Seegene Bull"},{"issue":"1","key":"2020081217003385900_i1543-2165-140-3-276-b08","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3802\/jgo.2009.20.1.1","article-title":"Current status of cervical cancer and HPV infection in Korea","volume":"20","author":"Kim","year":"2009","journal-title":"J Gynecol Oncol"},{"issue":"7","key":"2020081217003385900_i1543-2165-140-3-276-b09","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2020081217003385900_i1543-2165-140-3-276-b10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcv.2014.01.015","article-title":"Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection","volume":"59","author":"Kwon","year":"2014","journal-title":"J Clin Virol"},{"issue":"8","key":"2020081217003385900_i1543-2165-140-3-276-b11","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1128\/JCM.00824-08","article-title":"Human papillomavirus genotype specificity of Hybrid Capture 2","volume":"46","author":"Castle","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"5","key":"2020081217003385900_i1543-2165-140-3-276-b12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/JCM.00012-11","article-title":"Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening","volume":"49","author":"Poljak","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020081217003385900_i1543-2165-140-3-276-b13","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0703.S3-003","article-title":"Clinical validation of the BD Onclarity HPV assay using a non-inferiority test","author":"Ejegod","journal-title":"J Med Microb Diagn"},{"issue":"11","key":"2020081217003385900_i1543-2165-140-3-276-b14","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.01517-13","article-title":"The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening","volume":"51","author":"Heideman","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"11","key":"2020081217003385900_i1543-2165-140-3-276-b15","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1128\/JCM.05552-11","article-title":"Clinical validation of the Cobas 4800 HPV test for cervical screening purposes","volume":"49","author":"Heideman","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"7","key":"2020081217003385900_i1543-2165-140-3-276-b16","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/JCM.00633-13","article-title":"Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening","volume":"51","author":"Hesselink","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"12","key":"2020081217003385900_i1543-2165-140-3-276-b17","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1128\/JCM.01231-12","article-title":"Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of Hybrid Capture 2 for the purpose of cervical cancer screening","volume":"50","author":"Depuydt","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"9172","key":"2020081217003385900_i1543-2165-140-3-276-b18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(98)12490-X","article-title":"Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study","volume":"354","author":"Nobbenhuis","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"2020081217003385900_i1543-2165-140-3-276-b19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12275-013-3160-3","article-title":"Prevalence of human papillomavirus infection and genotype distribution determined by the cyclic-catcher melting temperature analysis in Korean medical checkup population","volume":"51","author":"Kim","year":"2013","journal-title":"J Microbiol"},{"issue":"3","key":"2020081217003385900_i1543-2165-140-3-276-b20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.11222","article-title":"Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study","volume":"106","author":"Dalstein","year":"2003","journal-title":"Int J Cancer"},{"issue":"2","key":"2020081217003385900_i1543-2165-140-3-276-b21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4132\/KoreanJPathol.2009.43.2.157","article-title":"Correlation analysis between cervicovaginal cytology and histopathologic diagnoses in cervical squamous cell neoplasm","volume":"43","author":"Lee","year":"2009","journal-title":"Korean J Pathol"},{"issue":"1","key":"2020081217003385900_i1543-2165-140-3-276-b22","first-page":"219","article-title":"Cervical cytology and HPV test in follow-up after conisation or LLETZ","volume":"34","author":"Ostoji\u0107","year":"2010","journal-title":"Coll Antropol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/140\/3\/276\/1445220\/arpa_2015-0117-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/140\/3\/276\/1445220\/arpa_2015-0117-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:32:21Z","timestamp":1764790341000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/140\/3\/article-p276.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2015-0117-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}